SCHEMBL6217005

SCHEMBL6217005

Cn1cccc1CC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
RECQL P46063 5/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
RAB9A P51151 6/20 0.46
KDM4E B2RXH2 5/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 8/20 0.44
HPGD P15428 3/20 0.44
NPC1 O15118 2/20 0.43
GFER P55789 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14828743 0.82 ALDH1A1 (0.53) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL867896 0.82 ALDH1A1 (0.53) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL2828704 0.79 RECQL (0.55) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL14665139 0.78 ALDH1A1 (0.47) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL14664143 0.77 MAPT (0.50) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL28630338 0.77 ALDH1A1 (0.52) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL687742 0.77 ALDH1A1 (0.49) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL7676895 0.74 RAB9A (0.48) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
SCHEMBL11531240 0.73 TSHR (0.53) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9
Acetic Acid SCHEMBL30330510 0.72 RAB9A (0.49) ALDH1A1RECQLCYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930107-B2 6-azauracil derivatives as thyroid receptor ligands PFIZER INC. (US) 2005-08-16 US disclosed
EP-1088819-B1 6-azauracil derivatives as thyroid receptor ligands PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6787652-B1 LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES PFIZER, INC. 2004-09-07 US disclosed
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands DOW ROBERT L (US) 2004-08-12 US disclosed
EP-1088819-A2 6-azauracil derivatives as thyroid receptor ligands Pfizer Products Inc. (US) 2001-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands TSHR, THRA, THRB ALDH1A1 291/4885RECQL 1284/4885CYP1A2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.